IL17A and psoriasis: Mastorino et al. reported on a case series of 1057 patients treated for psoriasis in our Turin Dermatology Clinic in which DS was 88% at 24 months for IL-23 inhibitors and 75% at 24 months for IL-17 inhibitors [15].